knowledge -WSS

knowledge

author：explore 2025-09-29 01:37:53 - browse：1764

Patient treated with Impella in the heart. -- health tech coverage from STAT — Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. Business Wire

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed.

Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. The FDA published a warning letter on Wednesday telling the company it should have submitted its software for approval before putting it on the market. The agency also took issue with Abiomed’s failure to report various problems with its heart pumps.

The letter comes a year after the Food and Drug Administration announced its intention to regulate more health software tools, sending the industry into an uproar.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： DeSantis can now import cheaper drugs. But will Biden get credit?

knowledge

WSS

HHS names first

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

UHS says company favors patients whose insurance pays more

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

How I ended up pumping milk in a bathroom stall at JPM 2024

knowledge

knowledge

Wikipedia

In Memoriam: Notable people who died in 2023

What causes rare myocarditis in young men after Covid vaccines?

DIEP, the 'gold standard' of breast reconstruction, is under threat

New Alzheimer's drugs heat up race for early detection blood tests

The cancer drug shortage isn’t new — and neither are the solutions

Why patients can’t get everything they want on drug pricing

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

HHS names first

How one medical school became remarkably diverse

Three issues to watch in global health in 2024

entertainment

'Investigate these claims': UFO transparency at center of House hearing

STAT Report: Patient voices and perspectives

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Dems pitch expanding Medicare power to negotiate drug prices

Roche’s Alnylam deal shows drug firms interested in heart drugs

hotspot

knowledge

knowledge

leisure time